Showing results (111-120 of 126) with videos related to
Sort By:
Pageof 13
The Prostate|May 10, 2022
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805Alicia K Morgans, Yu-Hui Chen, David F Jarrard, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2008
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxelKeith T Flaherty, Joan Schiller, Lynn M Schuchter, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2005
Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I studyGlenn Liu, Hope S Rugo, George Wilding, et al.Cancer Chemotherapy and Pharmacology|October 9, 2008
Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignanciesSteven Attia, Sherry Morgan-Meadows, Kyle D Holen, et al.European Urology Oncology|December 12, 2024
Digital Pathology-based Artificial Intelligence Biomarker Validation in Metastatic Prostate CancerMark C Markowski, Yi Ren, Meghan Tierney, et al.Molecular Oncology|September 10, 2022
Increased MYBL2 expression in aggressive hormone-sensitive prostate cancerYuki Yoshikawa, Konrad H Stopsack, Xin Victoria Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2018
Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology GuidelineJustin E Bekelman, R Bryan Rumble, Ronald C Chen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2018
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED TrialChristos E Kyriakopoulos, Yu-Hui Chen, Michael A Carducci, et al.European Urology|February 25, 2018
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 StudiesGwenaelle Gravis, Jean-Marie Boher, Yu-Hui Chen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2010
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancerDana Rathkopf, Glenn Liu, Michael A Carducci, et al.Pageof 13